Troglitazone Improves Recovery of Left Ventricular Function After Regional Ischemia in Pigs

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2000 Mar 15

PMID 10715264

Citations 22

Authors

P Zhu

L Lu

Y Xu

G G Schwartz

Affiliations

Soon will be listed here.

Abstract

Background: This study determined whether treatment of normal (nondiabetic) pigs with the insulin-sensitizing agent troglitazone improves recovery of left ventricular (LV) function after acute ischemia and whether such effects are associated with altered myocardial substrate metabolism.

Methods And Results: Juvenile pigs (n=6) were treated with troglitazone (75 mg. kg(-1). d(-1) PO) for 8 weeks. Untreated pigs (n=8) served as controls. Under anesthetized, open-chest conditions, pigs underwent 90 minutes of moderate regional LV ischemia and 90 minutes of reperfusion. Regional LV function was assessed with subendocardial sonomicrometry crystals. Fasting plasma insulin and free fatty acid levels were lower in troglitazone-treated pigs than in untreated pigs, whereas blood glucose did not differ between groups. These findings suggest that treatment enhanced systemic insulin sensitivity. Baseline hemodynamics and regional LV function did not differ between groups. After ischemia and reperfusion, systolic function (external work) of the ischemic region recovered to 44+/-6% of baseline in troglitazone-treated pigs versus 18+/-6% of baseline in untreated pigs (P<0.05). Regional diastolic function (maximum rate of wall expansion) recovered to 78+/-7% of baseline in treated pigs versus 52+/-7% of baseline in untreated pigs (P<0.05). Recovery of global LV systolic and diastolic function was also significantly greater in treated pigs. Myocardial glucose uptake did not differ between groups under any condition; however, net myocardial lactate uptake after reperfusion was 7 times greater in troglitazone-treated pigs than in untreated pigs, suggesting that treatment enhanced myocardial carbohydrate oxidation after reperfusion.

Conclusions: In nondiabetic pigs, chronic troglitazone treatment improves recovery of LV systolic and diastolic function after acute ischemia.

Citing Articles

The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity.

Karwi Q, Sun Q, Lopaschuk G Cells. 2021; 10(11).

PMID: 34831481 PMC: 8621814. DOI: 10.3390/cells10113259.

Untangling the Cooperative Role of Nuclear Receptors in Cardiovascular Physiology and Disease.

Paredes A, Santos-Clemente R, Ricote M Int J Mol Sci. 2021; 22(15).

PMID: 34360540 PMC: 8346021. DOI: 10.3390/ijms22157775.

Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications.

Pasqua T, Rocca C, Giglio A, Angelone T J Clin Med. 2021; 10(4).

PMID: 33673114 PMC: 7918460. DOI: 10.3390/jcm10040721.

Identification of potential molecular mechanisms and small molecule drugs in myocardial ischemia/reperfusion injury.

Jiang T, Liu Y, Chen B, Si L Braz J Med Biol Res. 2020; 53(9).

PMID: 32696819 PMC: 7372942. DOI: 10.1590/1414-431x20209717.

PPARγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts.

Riess M, Elorbany R, Weihrauch D, Stowe D, Camara A Cells. 2020; 9(1).

PMID: 31968546 PMC: 7017211. DOI: 10.3390/cells9010252.

References

Komers R, Vrana A . Thiazolidinediones--tools for the research of metabolic syndrome X. Physiol Res. 1998; 47(4):215-25. View

Sparano N, Seaton T . Troglitazone in type II diabetes mellitus. Pharmacotherapy. 1998; 18(3):539-48. View

Nakamura Y, Ohya Y, Onaka U, Fujii K, Abe I, Fujishima M . Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol. 1998; 123(4):675-82. PMC: 1565220. DOI: 10.1038/sj.bjp.0701669. View

Schwartz S, Raskin P, Fonseca V, Graveline J . Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med. 1998; 338(13):861-6. DOI: 10.1056/NEJM199803263381302. View

Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M . Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun. 1997; 235(1):113-6. DOI: 10.1006/bbrc.1997.6512. View

Ghazzi M, Perez J, Antonucci T, Driscoll J, Huang S, Faja B . Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes. 1997; 46(3):433-9. DOI: 10.2337/diab.46.3.433. View

Schwartz G, Xu Y, Greyson C, Cohen J, Lu L . Low-dose inotropic stimulation during left ventricular ischaemia does not worsen post-ischaemic dysfunction. Cardiovasc Res. 1996; 32(6):1024-37. DOI: 10.1016/s0008-6363(96)00150-2. View

Lopaschuk G, Stanley W . Glucose metabolism in the ischemic heart. Circulation. 1997; 95(2):313-5. DOI: 10.1161/01.cir.95.2.313. View

Shimoyama M, Ogino K, Tanaka Y, Ikeda T, Hisatome I . Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes. 1999; 48(3):609-15. DOI: 10.2337/diabetes.48.3.609. View

10.

Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V . Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998; 338(13):867-72. DOI: 10.1056/NEJM199803263381303. View

11.

Randle P . Regulation of glycolysis and pyruvate oxidation in cardiac muscle. Circ Res. 1976; 38(5 Suppl 1):I8-15. View

12.

Wisneski J, Gertz E, Neese R, Gruenke L, Morris D, Craig J . Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest. 1985; 76(5):1819-27. PMC: 424216. DOI: 10.1172/JCI112174. View

13.

Eberli F, Weinberg E, Grice W, Horowitz G, Apstein C . Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res. 1991; 68(2):466-81. DOI: 10.1161/01.res.68.2.466. View

14.

Schwartz G, Greyson C, Wisneski J, Garcia J, Steinman S . Relation among regional O2 consumption, high-energy phosphates, and substrate uptake in porcine right ventricle. Am J Physiol. 1994; 266(2 Pt 2):H521-30. DOI: 10.1152/ajpheart.1994.266.2.H521. View

15.

Lewandowski E, WHITE L . Pyruvate dehydrogenase influences postischemic heart function. Circulation. 1995; 91(7):2071-9. DOI: 10.1161/01.cir.91.7.2071. View

16.

Lu L, Xu Y, Greyson C, Ursell P, Schwartz G . Non-elastic deformation of myocardium in low-flow ischemia and reperfusion: ultrastructure-function relations. J Mol Cell Cardiol. 1999; 31(5):1157-69. DOI: 10.1006/jmcc.1999.0948. View

17.

Bahr M, Spelleken M, Bock M, von Holtey M, Kiehn R, Eckel J . Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia. 1996; 39(7):766-74. DOI: 10.1007/s001250050509. View

18.

Shimabukuro M, HIGA S, Shinzato T, Nagamine F, Komiya I, Takasu N . Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism. 1996; 45(9):1168-73. DOI: 10.1016/s0026-0495(96)90018-9. View

19.

Okuda K, Nohara R, Fujita M, Tamaki N, Konishi J, Sasayama S . Improvement of myocardial ischemic dysfunction with dichloroacetic acid: experimental study by repeated ischemia in dogs. J Cardiovasc Pharmacol. 1995; 26(6):990-9. DOI: 10.1097/00005344-199512000-00021. View

20.

Yagi N, Takasu N, HIGA S, Ishikawa K, Murakami K, MIMURA G . Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. Horm Metab Res. 1995; 27(10):439-41. DOI: 10.1055/s-2007-979997. View